Affimed Therapeutics has raised $15.7 million (€12.1 million) in Series E financing led by existing investors Aeris Capital, BioMedInvest, LSP Life Sciences Partners, Novo Nordisk and OrbiMed Advisors. As part of the financing, Affimed has signed a $14 million (€10.8 million) loan agreement with Perceptive Advisors. The company, which set the terms of its IPO a couple days ago, last raised funds in a €5.5 million ($20.1 million) Series D round in 2012. Proceeds from the financing will go to the continued clinical development of its cancer immunotherapies. Affimed will trade on the NASDAQ under the symbol AFMD when it hits the public markets.